A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

Study acronym: REGISTEM
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 years 11 months later Jun 2026 → Jun 2032
See other at-risk trials from Spanish Breast Cancer Research Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 2026 to Jun 2032
    • Eligibility criteria expanded, about 5 words
  2. 2 versions Re-verified since Feb 11, 2025, no change to tracked fieldsv12-v13
  3. Primary and study completion dates: Jun 2025 to Jun 2026
    • Enrollment target: 1400 to 1867
    • Eligibility criteria expanded, about 16 words
    • Site details revised at 1 of 40 sites
    v11
  4. Primary and study completion dates: Jun 2024 to Jun 2025v10
  5. Secondary endpoints: 9 to 4v9
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Study sites: 41 to 40
    • Eligibility criteria expanded, about 3 words
    v7
  3. Start date: Jun 2016 to Aug 2016
    • Secondary endpoints revised (9)
    • Study description expanded, about 248 words
    v6
  4. Study sites: 39 to 41v5
  5. Site details revised at 3 of 39 sitesv4
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 41 to 39
    v3
  7. Secondary endpoints revised (9)v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Trial Details
NCT Number NCT02819882
Lead Sponsor Spanish Breast Cancer Research Group
Collaborators: Hoffmann-La Roche, Novartis, AstraZeneca, Pfizer, Celgene
Conditions
(from sponsor)		 Breast Neoplasms
Related terms Breast Neoplasms, Neoplasm Metastasis
Enrollment 1,867 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov